Compare ORCL & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORCL | MRK |
|---|---|---|
| Founded | 1977 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.1B | 317.8B |
| IPO Year | 2005 | 1995 |
| Metric | ORCL | MRK |
|---|---|---|
| Price | $157.65 | $150.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 36 | 17 |
| Target Price | ★ $260.11 | $125.59 |
| AVG Volume (30 Days) | ★ 18.0M | 7.7M |
| Earning Date | 06-10-2026 | 04-30-2026 |
| Dividend Yield | 1.22% | ★ 3.06% |
| EPS Growth | ★ 34.33 | 8.01 |
| EPS | ★ 5.83 | N/A |
| Revenue | ★ $67,357,000,000.00 | $65,011,000,000.00 |
| Revenue This Year | $19.50 | $3.61 |
| Revenue Next Year | $31.91 | $5.41 |
| P/E Ratio | $26.67 | ★ N/A |
| Revenue Growth | ★ 17.35 | 1.31 |
| 52 Week Low | $114.50 | $77.58 |
| 52 Week High | $345.72 | $157.00 |
| Indicator | ORCL | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 58.39 | 65.79 |
| Support Level | $136.56 | $110.22 |
| Resistance Level | $164.31 | $157.00 |
| Average True Range (ATR) | 5.58 | 3.88 |
| MACD | 0.47 | 0.00 |
| Stochastic Oscillator | 93.28 | 78.26 |
Oracle provides enterprise applications and infrastructure offerings through a variety of flexible IT deployment models, including on-premises, cloud-based, and hybrid. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system, which is commonly used by the world's largest companies for high-volume online transaction processing workloads. Besides databases, Oracle also sells enterprise resource planning platforms and cloud infrastructure that play an increasingly important role in large language model training and inferencing.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).